GOU115/Video
TARGET AUDIENCE
This activity is intended for gynecologic and medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers. OVERVIEW OF ACTIVITY LEARNING OBJECTIVES
ACCREDITATION STATEMENT ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Robert L Coleman, MD Advisory Committee: Abbott Laboratories, AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences Ltd, Celgene Corporation, Cerulean Pharma Inc, Clovis Oncology, CritiTech Inc, Eisai Inc, Genentech BioOncology, Genmab, GlaxoSmithKline, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Merrimack Pharmaceuticals Inc, Nektar, Takeda Oncology, VentiRx Pharmaceuticals Inc; Consulting Agreement: Celgene Corporation; Contracted Research: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, EMD Serono Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Takeda Oncology. Bradley J Monk, MD Consulting Agreements: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cerulean Pharma Inc, Genentech BioOncology, GlaxoSmithKline, Gradalis Inc, ImmunoGen Inc, Merck, Pfizer Inc, Roche Laboratories Inc, TESARO Inc, Verastem Inc, Vermillion Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Morphotek Inc, Novartis Pharmaceuticals Corporation, TESARO Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Myriad Genetic Laboratories Inc, Roche Laboratories Inc. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. Hardware/Software Requirements: Last review date: November 2015 |